

Christopher Hourigan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5358178/publications.pdf>

Version: 2024-02-01

118
papers

6,076
citations

172207

29
h-index

82410

72
g-index

126
all docs

126
docs citations

126
times ranked

7755
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	2.5	5
2	Utility of plasma cell-free DNA for <i>de novo</i> detection and quantification of clonal hematopoiesis. <i>Haematologica</i> , 2022, 107, 1815-1826.	1.7	3
3	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
4	Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 73-77.	1.0	6
5	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. <i>Blood</i> , 2022, 133, e003392.		34
6	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 911-917.	1.3	18
7	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15
8	Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. <i>JCO Precision Oncology</i> , 2021, 5, 265-274.	1.5	13
9	Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 483.e1-483.e6.	0.6	52
10	Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. <i>Leukemia</i> , 2021, 35, 1529-1538.	3.3	48
11	Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. <i>Blood Advances</i> , 2021, 5, 1757-1759.	2.5	9
12	Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0249087.	1.1	1
13	Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis. <i>Blood Cancer Discovery</i> , 2021, 2, 319-325.	2.6	24
14	Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes. <i>Cancer Research</i> , 2021, 81, CT138-CT138.	0.4	2
15	Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. <i>Journal of Clinical Oncology</i> , 2021, 39, 2413-2415.	0.8	1
16	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	0.6	15
17	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
18	Detectable mutations precede late myeloid neoplasia in aplastic anemia. <i>Haematologica</i> , 2021, 106, 647-650.	1.7	10

#	ARTICLE	IF	CITATIONS
19	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2021, 138, 2753-2767.	0.6	305
20	Evaluation of a Rapid Automated Next Generation Sequencing Assay for Precision Medicine in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4444-4444.	0.6	1
21	Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis. <i>Blood</i> , 2021, 138, 414-414.	0.6	1
22	Highly Multiplexed Cell Surface Immunophenotyping with Genotyping and Concurrent Transcriptomic Analysis of <i>NPM1</i> mutated Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1288-1288.	0.6	0
23	Single-Cell Transcriptomic and Proteomic Analysis of Acute Myeloid Leukemia (AML) Patients with Abnormalities on Chromosome 7. <i>Blood</i> , 2021, 138, 1289-1289.	0.6	1
24	Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab. <i>Blood</i> , 2021, 138, 1846-1846.	0.6	0
25	Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Atherosclerosis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 912-915.e1.	0.3	9
26	Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 843-850.	1.3	32
27	Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 77-85.	1.2	34
28	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 1273-1283.	0.8	281
29	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2020, 6, 1890.	3.4	207
30	American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. <i>Blood Advances</i> , 2020, 4, 3528-3549.	2.5	113
31	Somatic Mutations in <i>UBA1</i> and Severe Adult-Onset Autoinflammatory Disease. <i>New England Journal of Medicine</i> , 2020, 383, 2628-2638.	13.9	580
32	Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects. <i>American Journal of Hematology</i> , 2020, 95, 662-671.	2.0	7
33	Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 135, 1185-1188.	0.6	29
34	Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 367-379.	2.5	29
35	Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Hematology International</i> , 2020, 2, 27.	0.7	5
36	B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia. <i>Clinical Hematology International</i> , 2020, 2, 125.	0.7	3

#	ARTICLE	IF	CITATIONS
37	Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies. <i>Blood</i> , 2020, 136, 16-17.	0.6	0
38	Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL. <i>Blood</i> , 2020, 136, 42-44.	0.6	0
39	Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults. <i>Blood</i> , 2020, 136, 41-42.	0.6	3
40	A Prospective Pilot Study to Evaluate Molecular Changes in the Hematopoietic System after Receipt of Chemotherapy or Radiotherapy and Its Clinical Implications Among Racially Diverse Breast Cancer Survivors: Breast Survivorchip Study. <i>Blood</i> , 2020, 136, 34-35.	0.6	8
41	Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation. <i>Leukemia Research Reports</i> , 2019, 12, 100176.	0.2	11
42	Heterogeneity in refractory acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10494-10503.	3.3	40
43	The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation. <i>Genes and Development</i> , 2019, 33, 482-497.	2.7	74
44	MRD evaluation of AML in clinical practice: are we there yet?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 557-569.	0.9	27
45	Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. <i>Blood Advances</i> , 2019, 3, 980-983.	2.5	5
46	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. <i>Neurosurgery</i> , 2019, 84, 945-953.	0.6	24
47	Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 297-304.	1.7	33
48	Refining AML outcome prediction. <i>Leukemia</i> , 2019, 33, 283-284.	3.3	4
49	Pathogenic TERT promoter variants in telomere diseases. <i>Genetics in Medicine</i> , 2019, 21, 1594-1602.	1.1	37
50	MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. <i>Leukemia Research</i> , 2019, 76, 70-75.	0.4	33
51	The distribution of Tâ€cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1470-1481.	2.0	229
52	A Novel Proteomic Profiling of the Bone Marrow Microenvironment Reveals Elevated Levels of the Chemokine CCL23 Isoforms in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2709-2709.	0.6	0
53	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018, 131, 1275-1291.	0.6	796
54	Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 109-121.	1.1	9

#	ARTICLE	IF	CITATIONS
55	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. <i>Clinical Cancer Research</i> , 2018, 24, 1019-1029.	3.2	87
56	Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. <i>JCI Insight</i> , 2018, 3, .	2.3	135
57	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
58	Leukaemia risk associated with low-dose radiation. <i>Lancet Haematology</i> , the, 2018, 5, e324-e325.	2.2	3
59	Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. <i>Frontiers in Oncology</i> , 2018, 8, 669.	1.3	15
60	Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1437-1437.	0.6	22
61	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. <i>Haematologica</i> , 2017, 102, 865-873.	1.7	206
62	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. <i>Blood Reviews</i> , 2017, 31, 185-192.	2.8	83
63	A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission. <i>Journal of Palliative Medicine</i> , 2017, 20, 1267-1273.	0.6	8
64	Measurable residual disease testing in acute myeloid leukaemia. <i>Leukemia</i> , 2017, 31, 1482-1490.	3.3	197
65	The Prognostic Significance of Measurable (‘‘Minimal’’) Residual Disease in Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 547-556.	1.2	19
66	Haplo, we have a problem. <i>Blood</i> , 2017, 130, 1180-1180.	0.6	0
67	Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated <i>Fusarium solani</i> infection. <i>Leukemia Research Reports</i> , 2017, 8, 4-6.	0.2	9
68	Immunological effects of hypomethylating agents. <i>Expert Review of Hematology</i> , 2017, 10, 745-752.	1.0	46
69	Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2017, 6, 87.	1.0	24
70	Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. <i>Journal of Translational Medicine</i> , 2017, 15, 155.	1.8	35
71	Editorial (Thematic Issue: Targets for Immunotherapy in Acute Leukemia). <i>Current Drug Targets</i> , 2017, 18, 256-256.	1.0	2
72	Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia. <i>Current Drug Targets</i> , 2017, 18, 296-303.	1.0	14

#	ARTICLE	IF	CITATIONS
73	When the Minimal Becomes Measurable. <i>Journal of Clinical Oncology</i> , 2016, 34, 2557-2558.	0.8	26
74	Accurate Medicine: Indirect Targeting of NPM1-Mutated AML. <i>Cancer Discovery</i> , 2016, 6, 1087-1089.	7.7	1
75	Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1974-1982.	2.0	23
76	Precision medicine for acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 1-3.	1.0	14
77	CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2016, 24, 815-822.	1.0	6
78	Increased Frequencies of PD-1+ CD8+ Marrow-Infiltrating Lymphocytes Associated with Highly Clonal T-Lymphocyte Expansions in Relapsed and Refractory AML Patients but Not Healthy Adults. <i>Blood</i> , 2016, 128, 1644-1644.	0.6	5
79	Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2015, 4, 665-695.	1.0	98
80	Identification of novel microRNA signatures linked to acquired aplastic anemia. <i>Haematologica</i> , 2015, 100, 1534-1545.	1.7	29
81	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 189-196.	1.3	7
82	A multigene array for measurable residual disease detection in AML patients undergoing SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 642-651.	1.3	33
83	Acute Myeloid Leukemia: Introduction. <i>Seminars in Hematology</i> , 2015, 52, 149.	1.8	2
84	Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 184-192.	1.8	32
85	Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1138-1140.	1.3	3
86	Development of Somatic NRAS Mutation Associated with Rapid Transition from Germline GATA2 Mutation Associated Myelodysplastic Syndrome to Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3616-3616.	0.6	1
87	Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile. <i>Blood</i> , 2015, 126, 3427-3427.	0.6	0
88	Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct. <i>Blood</i> , 2015, 126, 3212-3212.	0.6	0
89	Adult Acute Myeloid Leukemia Long-Term Survivors. <i>Journal of Leukemia (Los Angeles, Calif)</i> , 2014, 02, .	0.1	14
90	Contrast enhanced cardiac CT reveals coronary artery disease in 45% of asymptomatic allo-SCT long-term survivors. <i>Bone Marrow Transplantation</i> , 2014, 49, 451-452.	1.3	9

#	ARTICLE	IF	CITATIONS
91	Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. <i>Leukemia</i> , 2014, 28, 1167-1170.	3.3	33
92	Next Generation MRD. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1259-1260.	2.0	5
93	Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia. <i>Leukemia Research Reports</i> , 2014, 3, 46-48.	0.2	1
94	Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 154-163.	2.0	36
95	Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. <i>Experimental Hematology</i> , 2014, 42, 83-89.	0.2	26
96	The clinical and financial burden of pre-emptive management of Cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches. <i>Cytotherapy</i> , 2014, 16, 927-933.	0.3	56
97	Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 209-213.	2.0	13
98	Reprint of: Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S8-S17.	2.0	3
99	CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3898-3898.	0.6	0
100	Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2550-2550.	0.6	0
101	Minimal residual disease in acute myeloid leukaemia. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 460-471.	12.5	168
102	Personalized Therapy for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1336-1338.	7.7	12
103	Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2563-2564.	0.6	4
104	Post-Transplant Pulmonary Function Abnormalities Nadir At Five Years and Then Fully Normalize by the Second Decade in Allogeneic Stem Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S151.	2.0	0
105	Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. <i>Blood Cancer Journal</i> , 2013, 3, e145-e145.	2.8	21
106	High Levels Of IL-27 Occur In Newly Diagnosed Acute Myeloid Leukemia (AML) and May Influence Outcome By Suppressing T Cell Function. <i>Blood</i> , 2013, 122, 2567-2567.	0.6	1
107	Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. <i>Blood</i> , 2013, 122, 3885-3885.	0.6	5
108	Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome. <i>Blood</i> , 2013, 122, 593-593.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Barrett's, blood groups and progression to oesophageal cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 801-806.	0.8	16
110	Evaluation of Current Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 309-324.	1.0	18
111	New considerations in the design of clinical trials for the treatment of acute leukemia. <i>Clinical Investigation</i> , 2011, 1, 509-517.	0.0	7
112	Development of therapeutic agents for older patients with acute myelogenous leukemia. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 669-77.	2.3	10
113	The molecular basis of coeliac disease. <i>Clinical and Experimental Medicine</i> , 2006, 6, 53-59.	1.9	26
114	The structure of the human allo-ligand HLA-B*3501 in complex with a cytochrome p450 peptide: Steric hindrance influences TCR allo-recognition. <i>European Journal of Immunology</i> , 2006, 36, 3288-3293.	1.6	10
115	Are medical schools fit for graduates?. <i>BMJ: British Medical Journal</i> , 2005, 331, 1084.1.	2.4	0
116	Registering organ donor preferences - a third way?. <i>British Journal of General Practice</i> , 2005, 55, 805.	0.7	2
117	A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using $\hat{1}\pm 3$ Domain Mutants of MHC Class I/Peptide Complex. <i>Immunity</i> , 2001, 14, 591-602.	6.6	70
118	The Human CD8 Coreceptor Effects Cytotoxic T Cell Activation and Antigen Sensitivity Primarily by Mediating Complete Phosphorylation of the T Cell Receptor $\hat{1}\eta$ Chain. <i>Journal of Biological Chemistry</i> , 2001, 276, 32786-32792.	1.6	138